Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer

Published:2022-12-25 Issue:6 Volume:4 Page:301-308
ISSN:2434-9186
Container-title:Global Health & Medicine
language:en
Short-container-title:GHM

Author:

Karayama Masato¹,Mizoguchi Yukihiro²,Inoue Yusuke³,Hozumi Hironao³,Suzuki Yuzo³,Furuhashi Kazuki³,Fujisawa Tomoyuki³,Enomoto Noriyuki³,Nakamura Yutaro³,Inui Naoki⁴,Suda Takafumi³,Kitano Shigehisa⁵,Aoki Kazunori²,Yamada Yasuhide¹

Affiliation:

1. Department of Medical Oncology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

2. Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan.

3. Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

4. Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine, Hamamatsu, Japan.

5. Division of Cancer Immunotherapy Development, Advanced Medical Development Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan.

Publisher

National Center for Global Health and Medicine (JST)

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/ghm/4/6/4_2022.01052/_pdf

Reference27 articles.

1. 1. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015; 26:1824-1829.

2. 2. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018; 36:1714-1768.

3. 3. Mazzaschi G, Facchinetti F, Missale G, Canetti D, Madeddu D, Zecca A, Veneziani M, Gelsomino F, Goldoni M, Buti S, Bordi P, Aversa F, Ardizzoni A, Quaini F, Tiseo M. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer. 2019; 127:153-163.

4. 4. Youn JI, Park SM, Park S, et al. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Sci Rep. 2020; 10:9050.

5. 5. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. J Immunother Cancer. 2019; 7:306.